Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 12/20 | 0.45 |
| ▸ | CTSG | P08311 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699074 | 1.00 | CMA1 (0.45) | CMA1CTSGKDM4EALDH1A1HPGD | |
| SCHEMBL13822648 | 0.94 | FABP4 (0.42) | CMA1CTSGKDM4EALDH1A1HPGD | |
| SCHEMBL3689406 | 0.89 | PGR (0.38) | — | |
| SCHEMBL3686182 | 0.85 | CMA1 (0.38) | CMA1CTSG | |
| SCHEMBL3687513 | 0.84 | CMA1 (0.38) | CMA1CTSGKDM4EMAPT | |
| SCHEMBL3701617 | 0.83 | GAA (0.42) | KDM4EALDH1A1 | |
| SCHEMBL3683080 | 0.83 | CMA1 (0.35) | CMA1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3695212 | 0.83 | CMA1 (0.35) | CMA1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3683076 | 0.83 | CMA1 (0.35) | CMA1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3690021 | 0.82 | CMA1 (0.49) | CMA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377949-B2 | Quinazolinedione chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | CMA1, CTSC, TPSG1 | CMA1 1/4885CTSG 22/4885KDM4E 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.